Related Experiment Video
Updated: May 8, 2026
03:32
Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment
Published on: December 27, 2024
Post-surgical chemotherapy versus surgery alone for resectable gastric cancer
Rafael Diaz-Nieto1, Rafael Orti-Rodríguez, Marc Winslet
1HPB Surgery and Liver Transplant Unit, Royal Free Hospital, Pond Street, London, UK, NW3.
The Cochrane Database of Systematic Reviews
|September 4, 2013
Summary
Post-surgical chemotherapy improves survival for resectable gastric cancer patients. Routine use is recommended, but further trials are needed to clarify its role at different disease stages.
Area of Science:
- Oncology
- Surgical Oncology
- Gastroenterology
Background:
- Gastric cancer surgery is the primary treatment.
- Adjuvant chemotherapy may improve survival but carries risks and its benefit is debated.
- Evidence on routine use of post-surgical chemotherapy is inconclusive.
Purpose of the Study:
- To evaluate the efficacy of post-surgical chemotherapy in resectable gastric cancer.
- To determine if routine use of adjuvant chemotherapy is warranted.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials (RCTs).
- Searched major databases including Cochrane CENTRAL, MEDLINE, and EMBASE up to July 2013.
- Analyzed data using fixed- and random-effects models, calculating hazard ratios for overall survival (OS) and disease-free survival (DFS).
Main Results:
- Included 34 studies with 7824 patients; 15 reported DFS.
- Post-surgical chemotherapy significantly improved OS (HR 0.85; 95% CI 0.80-0.90) and DFS (HR 0.79; 95% CI 0.72-0.87).
- All included trials had a high risk of bias; quality of life data was unavailable.
Conclusions:
- Post-surgical chemotherapy should be routinely considered for resectable gastric cancer.
- Further high-quality RCTs are necessary to define its role across different disease stages.
